These findings highlight that the regional differences observed in the immunophenotypes in glioblastoma are clinically relevant and that high TREM2/CD32a/PD-L1 expression in the leading edge of glioblastomas portends a poor prognosis independent of clinical variables. Here, FCGR2A is linked to glioblastoma.